Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Modified Liangfu Granules (Xinjia Liangfu Granules) is a traditional Chinese medicine (TCM) formulation developed for the treatment of gastric cancer, specifically targeting blood hypercoagulability. The formula is a modification of the classic Liangfu Wan, which traditionally consists of *Rhizoma Alpiniae Officinarum* (Gao Liang Jiang) and *Rhizoma Cyperi* (Xiang Fu). It is primarily studied by researchers at Dongzhimen Hospital, affiliated with the Beijing University of Chinese Medicine, often in combination with conventional Western medicine. The granules are designed to warm the stomach, regulate Qi, and improve blood circulation, thereby addressing the 'blood stasis' and 'Qi stagnation' patterns associated with malignancy-induced hypercoagulable states.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Modified Liangfu Granules.